Regeneron, Roche’s antibody cocktail cuts COVID-19 hospitalizations, deaths by 70%, firm says


A mix monoclonal antibody cocktail produced by Regeneron and Roche has proven to scale back hospitalization or dying in COVID-19 sufferers by as a lot as 70%, a press launch posted Tuesday mentioned. The combo remedy, dubbed REGEN-COV, was being evaluated in a Phase 3 trial involving high-risk non-hospitalized COVID-19 sufferers.

REGEN-COV is comprised of casirivimab with imdevimab, and has already obtained emergency use authorization from the FDA within the U.S. Under the present EUA, the combo remedy is authorized to deal with non-hospitalized adults and adolescents with gentle to average signs of COVID-19 and who’re at excessive danger for growing extreme signs or the necessity for hospitalization.

The at the moment licensed dosage is 1,200 mg of casirivimab and 1,200 mg of imdevimab administered collectively as a single infusion inside 10 days of symptom onset.

SINOVAC SAYS IT’S COVID-19 VACCINE IS SAFE FOR CHILDREN AS YOUNG AS 3

The press launch, revealed by Regeneron Pharmaceuticals, Inc., additionally famous that the remedy decreased symptom length and {that a} companion Phase 2 trial noticed decreased viral load reductions in sufferers given low doses of REGEN-COV. The trial noticed sufferers given 300 mg intravenously and 600 mg subcutaneously, with researchers noting reductions over the primary seven days akin to these given the two,400 mg and 1,200 mg intravenous doses.

REGEN-COV is comprised of casirivimab with imdevimab, and has already obtained emergency use authorization from the FDA within the U.S.
(iStock)

“With roughly 60,000 newly identified people within the U.S. daily and 40,000 nonetheless within the hospital due to COVID-19, we’re dedicated to working with the federal government, well being care suppliers and others to help speedy and widespread adoption of REGEN-COV in applicable sufferers,” George D. Yancopoulos, M.D., Ph.D., Regeneron’s president and chief scientific officer, mentioned within the press launch. “We will quickly talk about the brand new information with regulatory authorities and request that the 1,200 mg dose be added to the U.S. Emergency Use Authorization, to ensure that the anticipated REGEN-COV provide to be obtainable to deal with much more sufferers.”

CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE

The firm mentioned there are ongoing trials involving REGEN-COV together with one within the U.Okay. learning the influence it could have on hospitalized sufferers. Another is evaluating the prevention of COVID-19 in family contacts of contaminated people.



Source hyperlink

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles